Clinical Features and HSCT Outcome for SCID in Turkey
Articles > Article · 2019
Authors: Aydan Ikinciogullari, Deniz Cagdas, Figen Dogu, Tuba Tugrul, Gulsum Karasu, Sule Haskologlu, Serap AKSOYLAR, Vedat Uygun, Alphan Kupesiz, Alisan Yildiran, Orhan Gursel, Can Ates, Atilla Elhan, Savaş KANSOY, Akif Yesilipek, Ilhan Tezcan
JOURNAL OF CLINICAL IMMUNOLOGY, Journal Indexed in SCI Expanded, International, 2019, vol 39, pp 316-323
DOI: 10.1007/s10875-019-00610-x
Summary
Severe combined immunodeficiency (SCID) is the most serious PID, characterized by T cell lymphopenia and lack of antigen-specific T cell and B cell immune responses, inevitably leading to death within the first year of life if hematopoietic stem cell transplantation (HSCT) is not performed.